Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer

Ebata, Tomoki; Hirano, Satoshi; Konishi, Masaru; Uesaka, Katsuhiko; Tsuchiya, Y.; Ohtsuka, Masayuki; Kaneoka, Yuji; Yamamoto, Masakazu; Ambo, Yoshiyasu; Shimizu, Yasuhiro; Ozawa, Fumiaki; Fukutomi, Akira; Ando, Masahiko; Nimura, Y; Nagino, Masato; Nakamori, Shoji; Ajiki, Tetsuo; Baba, Hideo; Yamaguchi, R; Kawai, Manabu; Nagano, Hiroaki; Miura, Fumihiko; Arai, Takaaki; Nishiwaki, Yoshiro; Kawasaki, S.; Shinchi, Hiroyuki; Shimoda, Mitsugi; Yamamoto, Yusuke; Endo, Itaru; Isaji, Shuji; Otsubo, Takehito; Ishihara, Shin; Takahara, Takeshi; Shimada, Mitsuo; Unno, Michiaki; Imamura, M; Ohkochi, Nobuhiro; Murakami, Yoshiaki; Fujimoto, Jiro; Ikuta, Shinichi; Fujino, Y; Uebayashi, Minoru; Ishiyama, Shuichi; Takakura, Norihisa; Kumamoto, Yusuke; Kato, Takehito; Yoshioka, Isaku; Üemoto, Shinji; Yanaga, Katsuhiko

doi:10.1002/bjs.10776

Public

Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer

Published in British journal of surgery • Feb 1, 2018

Authors:

Tomoki Ebata

Satoshi Hirano

Masaru Konishi

Abstract

Abstract Background Although some retrospective studies have suggested the value of adjuvant therapy, no recommended standard exists in bile duct cancer. The aim of this study was to test the hypothesis that adjuvant gemcitabine chemotherapy would improve survival probability in resected bile duct c...

Subject

Gemcitabine

Medicine

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!